骨转移患者的立体定向放疗:一个在生命最后一个月放疗率较低的选择性人群?
该回顾性分析(2010—2023年,1117例次)比较了骨转移患者接受传统单次8 Gy、传统多分次方案与立体定向单次12—16 Gy或多分次方案的结局。立体定向放疗组未完成分次治疗率4%、非立体定向组3%(p=1.0);8 Gy单次组生命最后30天内放疗率19%,立体定向单次组0%(p=0.01)。作者认为对选择性患者实施SBRT可降低未完成率和RT30,最佳选择标准尚待确定。
要点
- 8 Gy单次组生命最后30天内放疗率为19%,立体定向单次组为0%(p=0.01)。
- 多分次非立体定向组RT30为11%,多分次立体定向组为2%(p=0.08)。
- 未完成分次放疗在立体定向组为4%、非立体定向组为3%(p=1.0)。
核心结论
- 对选择性患者实施SBRT带来了较低的未完成率和生命最后30天内放疗率,最佳选择标准尚待确定。
- 在当前临床实践中,作者排除体能状态差、血液检查结果不利(LabBM评分高)以及不适合SBRT的进展病灶部位的患者。
- 已确立且获指南认可的短程方案,尤其是8 Gy单次治疗,仍代表一种重要的姑息治疗方法。
研究设计与样本
- 回顾性分析2010—2023年1117例次骨转移放疗患者。
- 比较传统单次8 Gy×1或多分次方案(常为4 Gy×5或3 Gy×10)与立体定向单次12—16 Gy×1或多分次方案。
- 除性别外,几乎所有基线变量分布不均。
主要发现
- 未完成分次放疗在立体定向组为4%、非立体定向组为3%(p=1.0)。
- 生命最后30天内放疗率:8 Gy单次组19% vs 立体定向单次组0%(p=0.01)。
- 生命最后30天内放疗率:多分次非立体定向组11% vs 多分次立体定向组2%(p=0.08)。
- 中位总生存期在8 Gy单次放疗后最短(4.2个月),在立体定向多分次治疗后最长(13.9个月)。
- 多因素Cox回归分析中,立体定向放疗和多分次治疗均未改善生存;与更长生存显著相关的因素包括更好的体能状态、更低的LabBM评分、照射区域外疾病稳定、异时性远处转移、从转移性疾病到骨放疗的更长间隔时间以及门诊状态。
关键数值与推荐
- 生命最后30天内放疗率在8 Gy单次组为19%、立体定向单次组为0%(p=0.01)。
- 生命最后30天内放疗率在多分次非立体定向组为11%、多分次立体定向组为2%(p=0.08)。
- 未完成分次放疗率在立体定向组为4%、非立体定向组为3%(p=1.0)。
临床怎么用
- 作者在结论中写道,当前临床实践中排除体能状态差、血液检查结果不利(LabBM评分高)以及不适合SBRT的进展病灶部位的患者。
- 作者认为已确立且获指南认可的短程方案,尤其是8 Gy单次治疗,仍代表一种重要的姑息治疗方法。
- 原文未据此给出其他推荐。
局限性
- 原文为回顾性分析。
- 除性别外,几乎所有基线变量分布不均。
- 最佳选择标准尚待确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Complex high-precision radiotherapy, such as stereotactic body radiotherapy (SBRT), should only be offered to patients with sufficiently long survival. In the context of bone metastases radiotherapy, low rates of treatment close to the end of life, e.g. last 30 days (RT30), may serve as a quality of care indicator. While traditional, pain-relieving short-course regimens have been studied comprehensively, real-world SBRT results are still limited. METHODS: Retrospective analysis (2010-2023, n = 1117 episodes) of patients with bone metastases treated with traditional single-fraction (8 Gy × 1) or multi-fraction regimens (often 4 Gy × 5 or 3 Gy × 10) compared to stereotactic single-fraction (12-16 Gy × 1) or multi-fraction regimens. RESULTS: Except for gender, almost all baseline variables were uneven distributed. Failure to complete fractionated radiotherapy was uncommon in the stereotactic (4%) and non-stereotactic group (3%), p = 1.0. With regard to RT30, relevant differences emerged (19% for 8-Gy single-fraction versus 0% for stereotactic single-fraction, p = 0.01). The corresponding figures were 11% for multi-fraction non-stereotactic and 2% for multi-fraction stereotactic, p = 0.08. Median overall survival was shortest after 8-Gy single-fraction irradiation (4.2 months) and longest after stereotactic multi-fraction treatment (13.9 months). Neither stereotactic radiotherapy nor multi-fraction treatment improved survival in multivariate Cox regression analysis. Factors significantly associated with longer survival included better performance status, lower LabBM score (5 standard blood test results), stable disease outside of irradiated area(s), metachronous distant metastases, longer time interval from metastatic disease to bone irradiation, and outpatient status. CONCLUSION: The implementation of SBRT for selected patients has resulted in low rates of non-completion and RT30. Optimal selection criteria remain to be determined, but in current clinical practice we exclude patients with poor performance status, unfavorable blood test results (high LabBM score) and progressive disease sites not amenable to SBRT. Established, guideline-endorsed short-course regimens, especially 8-Gy single-fraction treatment, continue to represent an important palliative approach.
引用
- Nieder C, Haukland EC, Stanisavljevic L, et al. Stereotactic radiotherapy for patients with bone metastases: a selected group with low rate of radiation treatment during the last month of life? Radiat Oncol. 2024. PMID: 39487535. doi:10.1186/s13014-024-02547-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。